Bicocca Open Archive

Logo unimib boa
GEETA, GEETA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.161
AS - Asia 1.456
EU - Europa 1.415
Continente sconosciuto - Info sul continente non disponibili 219
SA - Sud America 201
AF - Africa 47
OC - Oceania 8
Totale 6.507
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.023
SG - Singapore 485
IT - Italia 415
CN - Cina 343
DE - Germania 253
HK - Hong Kong 185
VN - Vietnam 171
RU - Federazione Russa 162
BR - Brasile 151
CA - Canada 113
SE - Svezia 112
IE - Irlanda 105
GB - Regno Unito 83
FR - Francia 71
IN - India 55
PL - Polonia 54
ID - Indonesia 38
BD - Bangladesh 32
UA - Ucraina 30
ES - Italia 23
TR - Turchia 23
FI - Finlandia 21
JP - Giappone 20
NL - Olanda 19
KR - Corea 16
BE - Belgio 15
ZA - Sudafrica 15
AR - Argentina 13
DK - Danimarca 12
MX - Messico 12
AT - Austria 10
SA - Arabia Saudita 10
CO - Colombia 9
VE - Venezuela 9
CH - Svizzera 8
IR - Iran 8
UZ - Uzbekistan 8
EC - Ecuador 7
MA - Marocco 7
MY - Malesia 7
PK - Pakistan 7
AE - Emirati Arabi Uniti 6
AU - Australia 6
IQ - Iraq 6
PE - Perù 6
CR - Costa Rica 5
DZ - Algeria 5
GR - Grecia 5
JO - Giordania 5
KE - Kenya 5
TN - Tunisia 5
CL - Cile 4
EU - Europa 4
NP - Nepal 4
OM - Oman 4
RO - Romania 4
TW - Taiwan 4
IL - Israele 3
JM - Giamaica 3
NO - Norvegia 3
EG - Egitto 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
KG - Kirghizistan 2
KW - Kuwait 2
LT - Lituania 2
PH - Filippine 2
SO - Somalia 2
TH - Thailandia 2
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
DO - Repubblica Dominicana 1
GA - Gabon 1
GH - Ghana 1
IS - Islanda 1
KZ - Kazakistan 1
LB - Libano 1
LY - Libia 1
MC - Monaco 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
SC - Seychelles 1
SN - Senegal 1
TO - Tonga 1
UY - Uruguay 1
Totale 6.292
Salva come PNG Salva come JPEG
Città #
Ann Arbor 673
Ashburn 299
Singapore 268
Frankfurt am Main 191
San Jose 185
Hong Kong 174
Milan 155
Chandler 124
Wilmington 118
Fairfield 107
Dublin 104
Toronto 77
New York 72
Los Angeles 70
Woodbridge 56
The Dalles 55
Beijing 51
Hanoi 50
Council Bluffs 49
Ho Chi Minh City 49
Houston 46
Dallas 44
Seattle 44
Dearborn 42
Santa Clara 42
Chicago 37
Lodz 36
Cambridge 33
Princeton 32
Jakarta 30
Columbus 27
Boardman 26
Shanghai 25
Phoenix 21
Buffalo 20
Munich 20
Lauterbourg 18
Hefei 17
Nanjing 16
Brussels 15
Moscow 15
Seoul 15
São Paulo 15
Da Nang 14
Fremont 14
Lawrence 14
Warsaw 13
Johannesburg 12
Orem 12
Rome 12
Changsha 11
London 11
Tokyo 11
Altamura 10
Hangzhou 10
Jacksonville 10
Ottawa 10
Trento 10
Brooklyn 9
Denver 9
Helsinki 9
Rio de Janeiro 9
Guangzhou 8
Haiphong 8
Nuremberg 8
San Diego 8
Turku 8
Andover 7
Atlanta 7
Boston 7
Dhaka 7
Istanbul 7
Jinan 7
Norwalk 7
Stockholm 7
Turin 7
Washington 7
Amsterdam 6
Edmonton 6
Kent 6
Montreal 6
Monza 6
Philadelphia 6
Poplar 6
Shenyang 6
Tianjin 6
Amman 5
Campinas 5
Corsico 5
Erzurum 5
Figino 5
Hebei 5
Kiev 5
Medellín 5
Nairobi 5
Nanchang 5
Naples 5
Redmond 5
Romola 5
Tashkent 5
Totale 4.007
Salva come PNG Salva come JPEG
Nome #
Lorlatinib treatment elicits multiple on- and off-target mechanisms of resistance in ALK-driven cancer 580
Long-term efficacy and safety of crizotinib in relapsed ALK positive lymphoma patients: clinical and biological correlates 474
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 469
In vitro and in vivo characterization of resistance to lorlatinib treatment in ALK mutated cancers 447
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 435
Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells 404
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 392
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 366
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 346
Recurrent somatic mutations of FAT family cadherins induce an aggressive phenotype and poor prognosis in anaplastic large cell lymphoma 329
New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients 323
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 313
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 301
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 294
We shall overcome (drug resistance) some day 288
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 260
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 255
Abstract 987: Novel ALK mutations in EML4::ALK+ NSCLC resistant to TKIs identified by liquid biopsy 231
Totale 6.507
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.055
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.055
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022176 0 0 0 25 16 16 20 9 13 15 26 36
2022/2023567 53 150 72 51 45 76 7 35 22 39 9 8
2023/2024361 7 10 20 17 32 93 58 24 37 14 10 39
2024/2025988 50 74 33 50 116 52 82 33 126 157 82 133
2025/20262.246 227 104 217 228 239 127 371 93 178 200 126 136
2026/2027512 84 89 182 157 0 0 0 0 0 0 0 0
Totale 6.507